The insanity of addiction treatment in America

References

• Abouk R, Pacula RL, Powell D. 2019. Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose. JAMA Intern Med. 179(6):805–811.
   PubMed Web of Science ®Google Scholar
• Adams JM. 2020. Making the case for syringe services programs. Public Health Rep. 135(1_suppl):10S–12S.
   PubMed Web of Science ®Google Scholar
• Ahmad FB, Rossen LM, Sutton P. 2021. Provisional drug overdose death counts. Maryland: National Center for Health Statistics.
   Google Scholar
• American Rescue Plan Act of 2021, H.R. 1319, 117th Cong 2021. https://www.congress.gov/bill/117th-congress/house-bill/1319/text.
   Google Scholar
• Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, Velzen EV, Palmateer N, Doyle JS, Hellard ME, Hutchinson SJ. 2014. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 43(1):235–248.
   PubMed Web of Science ®Google Scholar
• Behrends CN, Paone D, Nolan ML, Tuazon E, Murphy SM, Kapadia SN, Jeng PJ, Bayoumi AM, Kunins HV, Schackman BR. 2019. Estimated impact of supervised injection facilities on overdose fatalities and healthcare costs in New York City. J Subst Abuse Treat. 106:79–88.
   PubMed Web of Science ®Google Scholar
• Bill W. 1939. Alcoholics anonymous: the story of how more than one hundred men have recovered from alcoholism. New York: Alcoholics Anonymous World Services.
   Google Scholar
• Boyer EW. 2012. Management of opioid analgesic overdose. N Engl J Med. 367(2):146–155.
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Ellis MS, Chilcoat HD. 2018. Understanding the use of diverted buprenorphine. Drug Alcohol Depend. 193:117–123.
   PubMed Web of Science ®Google Scholar
• Clark AK, Wilder CM, Winstanley EL. 2014. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 8(3):153–163.
   PubMed Web of Science ®Google Scholar
• Coffin PO, Behar E, Rowe C, Santos G, Coffa D, Bald M, Vittinghoff E. 2016. Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med. 165(4):245–252.
   PubMed Web of Science ®Google Scholar
• Currie JM, Schnell MK, Schwandt H, Zhang J. 2021. Trends in drug overdose mortality in Ohio during the first 7 months of the COVID-19 pandemic. JAMA Netw Open. 4(4):e2114947.
   PubMed Web of Science ®Google Scholar
• Daniulaityte R, Nahhas RW, Silverstein S, Martins S, Zaragoza A, Moeller A, Carlson RG. 2019. Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: a latent class analysis. Drug Alcohol Depend. 204:107574.
   PubMed Web of Science ®Google Scholar
• Davis CS, Carr D. 2015. Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug Alcohol Depend. 157:112–120.
   PubMed Web of Science ®Google Scholar
• Fairley M, Humphreys K, Joyce VR, Bounthavong M, Trafton J, Combs A, Oliva EM, Goldhaber-Fiebert JD, Asch SM, Brandeau ML, et al. 2021. Cost-effectiveness of treatments for opioid use disorder. JAMA Psychiatry. 78(7):767–777.
   PubMed Web of Science ®Google Scholar
• Fernandes RM, Cary M, Duarte G, Jesus G, Alarcão J, Torre C, Costa S, Costa J, Carneiro AV. 2017. Effectiveness of needle and syringe programmes in people who inject drugs – an overview of systematic reviews. BMC Public Health. 17(1):2.
   PubMedGoogle Scholar
• Glober N, Mohler G, Huynh P, Arkins T, O’Donnell D, Carter J, Ray B. 2020. Impact of COVID-19 pandemic on drug overdoses in Indianapolis. J Urban Health. 97(6):802–807.
   PubMed Web of Science ®Google Scholar
• Hagan H, McGough JP, Thiede H, Hopkins S, Duchin J, Alexander ER. 2000. Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. J Subst Abuse Treat. 19(3):247–252.
   PubMed Web of Science ®Google Scholar
• Higashikawa Y, Suzuki S. 2008. Studies on 1-(2-phenethyl)-4-(N-propionylanilino) piperidine (fentanyl) and its related compounds. VI. Structure-analgesic activity relationship for fentanyl, methyl-substituted fentanyls and other analogues. Forensic Toxicol. 26(1):1–5.
   Web of Science ®Google Scholar
• Huhn AS, Hobelmann JG, Strickland JC, Oyler GA, Bergeria CL, Umbricht A, Dunn KE. 2020. Differences in availability and use of medications for opioid use disorder in residential treatment settings in the United States. JAMA Netw Open. 3(2):e1920843.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. 2007. Preventing HIV infection among injecting drug users in high-risk countries: an assessment of the evidence. Washington (DC): The National Academies Press.
   Google Scholar
• Irwin A, Jozaghi E, Weir BW, Allen ST, Lindsay A, Sherman SG. 2017. Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility. Harm Reduct J. 14(1):29.
   PubMedGoogle Scholar
• Jackson JR, Harle CA, Silverman RD, Simon K, Menachemi N. 2020. Characterizing variability in state-level regulations governing opioid treatment programs. J Subst Abuse Treat. 115:108008.
   PubMed Web of Science ®Google Scholar
• Kåberg M, Karlsson N, Discacciati A, Widgren K, Weiland O, Ekström AM, Hammarberg A. 2020. Significant decrease in injection risk behaviors among participants in a needle exchange programme. Infectious Diseases. 52(5):336–346.
   PubMed Web of Science ®Google Scholar
• Karamouzian M, Dohoo C, Forsting S, McNeil R, Kerr T, Lysyshyn M. 2018. Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver, Canada. Harm Reduct J. 15(1):8.
   PubMedGoogle Scholar
• Keane C, Egan JE, Hawk M. 2018. Effects of naloxone distribution to likely bystanders: results of an agent-based model. Int J Drug Policy. 55:61–69.
   PubMed Web of Science ®Google Scholar
• Kelly JF, Humphreys K, Ferri M. 2020. Alcoholics Anonymous and other 12-step programs for alcohol use disorder. Cochrane Database Syst Rev. 3(3):CD012880.
   PubMedGoogle Scholar
• Kerr T, Mitra S, Kennedy MC, McNeil R. 2017. Supervised injection facilities in Canada: past, present, and future. Harm Reduct J. 14(1):28.
   PubMed Web of Science ®Google Scholar
• Kral AH, Lambdin BH, Wenger LD, Davidson PJ. 2020. Evaluation of an unsanctioned safe consumption site in the United States. N Engl J Med. 383(6):589–590.
   PubMed Web of Science ®Google Scholar
• Krentzman AR. 2019. A full and thankful heart: writings about gratitude by Alcoholics Anonymous co-founder, Bill Wilson. Addict Res Theory. 27(6):451–461.
   Web of Science ®Google Scholar
• Krieger MS, Yedinak JL, Buxton JA, Lysyshyn M, Bernstein E, Rich JD, Green TC, Hadland SE, Marshall BDL. 2018. High willingness to use rapid fentanyl test strips among young adults who use drugs. Harm Reduct J. 15(1):2.
   PubMedGoogle Scholar
• Lambdin BH, Zibbell J, Wheeler E, Kral AH. 2018. Identifying gaps in the implementation of naloxone programs for laypersons in the United States. Int J Drug Policy. 52:52–55.
   PubMed Web of Science ®Google Scholar
• Langabeer JR, Champagne-Langabeer T, Yatsco AJ, O’Neal MM, Cardenas-Turanzas M, Prater S, Luber S, Stotts A, Fadial T, Khraish G, et al. 2021. Feasibility and outcomes from an integrated bridge treatment program for opioid use disorder. J Am Coll Emerg Physicians Open. 2(2):e12417.
   PubMedGoogle Scholar
• Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, Grebely J, Dumchev KV, Griffiths P, Hines L, et al. 2017. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. The Lancet Global Health. 5(12):e1208–e1220.
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY. 2018. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 169(3):137–145.
   PubMed Web of Science ®Google Scholar
• Lee HS, Engstrom M, Petersen SR. 2011. Harm reduction and 12 steps: complementary, oppositional, or something in-between? Subst Use Misuse. 46(9):1151–1161.
   PubMed Web of Science ®Google Scholar
• Leonard L, DeRubeis E, Pelude L, Medd E, Birkett N, Seto J. 2008. I inject less as I have easier access to pipes: injecting, and sharing of crack-smoking materials, decline as safer crack-smoking resources are distributed. Int J Drug Policy. 19(3):255–264.
   PubMed Web of Science ®Google Scholar
• MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, Taylor A, Roy K, Aspinall E, Goldberg D, et al. 2014. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy. 25(1):34–52.
   PubMed Web of Science ®Google Scholar
• Marshall BDL, Milloy M, Wood E, Montaner JSG, Kerr T. 2011. Reduction in overdose mortality after the opening of North America’s first medically supervised safer injecting facility: a retrospective population-based study. The Lancet. 377(9775):1429–1437.
   PubMed Web of Science ®Google Scholar
• Marx MA, Crape B, Brookmeyer RS, Junge B, Latkin C, Vlahov D, Strathdee SA. 2000. Trends in crime and the introduction of a needle exchange program. Am J Public Health. 90(12):1933–1936.
   PubMed Web of Science ®Google Scholar
• Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. 2021. Trends and geographic patterns in drug and synthetic opioid overdose deaths – United States, 2013-2019. MMWR Morb Mortal Wkly Rep. 70(6):202–207.
   PubMed Web of Science ®Google Scholar
• McCrae K, Tobias S, Grant C, Lysyshyn M, Laing R, Wood E, Ti L. 2020. Assessing the limit of detection of Fourier-transform infrared spectroscopy and immunoassay strips for fentanyl in a real-world setting. Drug Alcohol Rev. 39(1):98–102.
   PubMed Web of Science ®Google Scholar
• McElrath K. 2018. Medication-assisted treatment for opioid addiction in the United States: critique and commentary. Subst Use Misuse. 53(2):334–343.
   PubMed Web of Science ®Google Scholar
• McGowan CR, Harris M, Platt L, Hope V, Rhodes T. 2018. Fentanyl self-testing outside supervised injection settings to prevent opioid overdose: do we know enough to promote it? Int J Drug Policy. 58:31–36.
   PubMed Web of Science ®Google Scholar
• Nguyen TQ, Weir BW, Jarlais DC, Pinkerton SD, Holtgrave DR. 2014. Syringe exchange in the United States: a national level economic evaluation of hypothetical increases in investment. AIDS Behav. 18(11):2144–2155.
   PubMed Web of Science ®Google Scholar
• Park JN, Sherman SG, Rouhani S, Morales KB, McKenzie M, Allen ST, Marshall BDL, Green TC. 2019. Willingness to use safe consumption spaces among opioid users at high risk of fentanyl overdose in Baltimore, Providence, and Boston. J Urban Health. 96(3):353–366.
   PubMed Web of Science ®Google Scholar
• Peckham AM, Kehoe LG, Gray JR, Wakeman SE. 2021. Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: a retrospective case series. J Subst Abuse Treat. 126:108316.
   PubMed Web of Science ®Google Scholar
• Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, et al. 2017. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 9:CD012021.
   PubMed Web of Science ®Google Scholar
• Potier C, Laprévote V, Dubois-Arber F, Cottencin O, Rolland B. 2014. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 145:48–68.
   PubMed Web of Science ®Google Scholar
• Registration Requirements for Narcotic Treatment Programs with Mobile Components 2021., 86 Fed. Reg. 33861 (June 28, (to be codified at 21 CFR pts. 1300, 1301, & 1304).
   Google Scholar
• Rosenblatt RA, Andrilla CHA, Catlin M & Larson EH. 2015. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 13(1):23–26.
   PubMed Web of Science ®Google Scholar
• Santo T, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, Chen A, Tran LT, Bharat C, Padmanathan P, et al. 2021. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 78(9):979.
   PubMed Web of Science ®Google Scholar
• Snow RL, Simon RE, Jack HE, Oller D, Kehoe L, Wakeman SE. 2019. Patient experiences with a transitional, low-threshold clinic for the treatment of substance use disorder: a qualitative study of a bridge clinic. J Subst Abuse Treat. 107:1–7.
   PubMed Web of Science ®Google Scholar
• Stein BD, Saloner B, Schuler MS, Gurvey J, Sorbero M, Gordon AJ. 2021. Concentration of patient care among buprenorphine-prescribing clinicians in the US. JAMA. 325(21):2206–2208.
   PubMed Web of Science ®Google Scholar
• Stein BD, Smart R, Jones CM, Sheng F, Powell D, Sorbero M. 2021. Individual and community factors associated with naloxone co-prescribing among long-term opioid patients: a retrospective analysis. J Gen Intern Med. 36(10):2952–2957.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. 2020. Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville (MD): Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. 2021. Federal grantees may now use funds to purchase fentanyl test strips. https://www.samhsa.gov/newsroom/press-announcements/202104070200.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. 2021. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63 Publication No. PEP21-02-01-002. Rockville (MD): Substance Abuse and Mental Health Services Administration.
   Google Scholar
• Sullivan RW, Szczesniak LM, Wojcik SM. 2021. Bridge clinic buprenorphine program decreases emergency department visits. J Subst Abuse Treat. 130:108410.
   PubMed Web of Science ®Google Scholar
• Ti L, Tobias S, Lysyshyn M, Laing R, Nosova E, Choi J, Arredondo J, McCrae K, Tupper K, Wood E. 2020. Detecting fentanyl using point-of-care drug checking technologies: a validation study. Drug Alcohol Depend. 212:108006.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. 2018. Facing addiction in America: The Surgeon General’s spotlight on opioids. Office of the Surgeon General. Washington (DC): U.S. Department of Health and Human Services.
   Google Scholar
• U.S. Department of Health and Human Services. 2021. Practice guidelines for the administration of buprenorphine for treating opioid use disorder. https://www.federalregister.gov/documents/2021/04/28/2021-08961/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder.
   Google Scholar
• Volpe DA, Tobin GAM, Mellon RD, Katki AG, Parker RJ, Colatsky T, Kropp TJ, Verbois SL. 2011. Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharm. 59(3):385–390.
   PubMed Web of Science ®Google Scholar
• Wallace B, Pagan F, Pauly BB. 2019. The implementation of overdose prevention sites as a novel and nimble response during an illegal drug overdose public health emergency. Int J Drug Policy. 66:64–72.
   PubMed Web of Science ®Google Scholar
• Young S, Fairbairn N. 2018. Expanding supervised injection facilities across Canada: lessons from the Vancouver experience. Can J Public Health. 109(2):227–230.
   PubMed Web of Science ®Google Scholar
• Zampini GF. 2018. Evidence and morality in harm-reduction debates: can we use value-neutral arguments to achieve value-driven goals? Palgrave Commun. 4(1):62.
   Google Scholar